AnaptysBio Inc (ANAB) concluded trading on Wednesday at a closing price of $14.36, with 0.46 million shares of worth about $6.58 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -47.38% during that period and on January 08, 2025 the price saw a loss of about -3.17%. Currently the company’s common shares owned by public are about 30.43M shares, out of which, 26.01M shares are available for trading.
Stock saw a price change of 8.46% in past 5 days and over the past one month there was a price change of -42.12%. Year-to-date (YTD), ANAB shares are showing a performance of 8.46% which decreased to -36.38% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $12.51 but also hit the highest price of $41.31 during that period. The average intraday trading volume for AnaptysBio Inc shares is 608.60K. The stock is currently trading -4.36% below its 20-day simple moving average (SMA20), while that difference is down -26.70% for SMA50 and it goes to -46.44% lower than SMA200.
AnaptysBio Inc (NASDAQ: ANAB) currently have 30.43M outstanding shares and institutions hold larger chunk of about 103.95% of that.
The stock has a current market capitalization of $436.96M and its 3Y-monthly beta is at -0.03. It has posted earnings per share of -$6.07 in the same period. It has Quick Ratio of 10.23 while making debt-to-equity ratio of 4.35. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ANAB, volatility over the week remained 7.78% while standing at 8.79% over the month.
Stock’s fiscal year EPS is expected to drop by -0.07% while it is estimated to increase by 11.84% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on December 11, 2024 offering a Neutral rating for the stock and assigned a target price range of between $52 and $19 to it. On July 22, 2024, H.C. Wainwright Initiated their recommendations, while on July 19, 2024, JP Morgan Upgrade their ratings for the stock with a price target of $69. Stock get an Outperform rating from Leerink Partners on April 16, 2024.
